Insmed Statistics
Total Valuation
Insmed has a market cap or net worth of $13.09 billion. The enterprise value is $12.78 billion.
Important Dates
The last earnings date was Thursday, October 31, 2024, before market open.
| Earnings Date | Oct 31, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Insmed has 178.90 million shares outstanding. The number of shares has increased by 13.14% in one year.
| Current Share Class | 178.90M |
| Shares Outstanding | 178.90M |
| Shares Change (YoY) | +13.14% |
| Shares Change (QoQ) | +12.29% |
| Owned by Insiders (%) | 0.86% |
| Owned by Institutions (%) | 101.15% |
| Float | 166.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 33.16 |
| Forward PS | 131.78 |
| PB Ratio | 27.06 |
| P/TBV Ratio | 41.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 37.26 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.37, with a Debt / Equity ratio of 2.40.
| Current Ratio | 6.37 |
| Quick Ratio | 5.83 |
| Debt / Equity | 2.40 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.45 |
Financial Efficiency
Return on equity (ROE) is -890.75% and return on invested capital (ROIC) is -32.53%.
| Return on Equity (ROE) | -890.75% |
| Return on Assets (ROA) | -26.05% |
| Return on Capital (ROIC) | -32.53% |
| Revenue Per Employee | $376,050 |
| Profits Per Employee | -$947,681 |
| Employee Count | 912 |
| Asset Turnover | 0.20 |
| Inventory Turnover | 0.88 |
Taxes
In the past 12 months, Insmed has paid $3.44 million in taxes.
| Income Tax | 3.44M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +200.16% in the last 52 weeks. The beta is 1.12, so Insmed's price volatility has been higher than the market average.
| Beta (5Y) | 1.12 |
| 52-Week Price Change | +200.16% |
| 50-Day Moving Average | 72.04 |
| 200-Day Moving Average | 54.50 |
| Relative Strength Index (RSI) | 53.80 |
| Average Volume (20 Days) | 1,700,370 |
Short Selling Information
The latest short interest is 13.85 million, so 7.74% of the outstanding shares have been sold short.
| Short Interest | 13.85M |
| Short Previous Month | 13.70M |
| Short % of Shares Out | 7.74% |
| Short % of Float | 8.30% |
| Short Ratio (days to cover) | 11.79 |
Income Statement
In the last 12 months, Insmed had revenue of $342.96 million and -$864.29 million in losses. Loss per share was -$5.56.
| Revenue | 342.96M |
| Gross Profit | 264.92M |
| Operating Income | -703.93M |
| Pretax Income | -799.73M |
| Net Income | -864.29M |
| EBITDA | -695.06M |
| EBIT | -703.93M |
| Loss Per Share | -$5.56 |
Full Income StatementBalance Sheet
The company has $1.47 billion in cash and $1.16 billion in debt, giving a net cash position of $307.99 million or $1.72 per share.
| Cash & Cash Equivalents | 1.47B |
| Total Debt | 1.16B |
| Net Cash | 307.99M |
| Net Cash Per Share | $1.72 |
| Equity (Book Value) | 483.42M |
| Book Value Per Share | 2.70 |
| Working Capital | 1.39B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$618.72 million and capital expenditures -$17.30 million, giving a free cash flow of -$636.03 million.
| Operating Cash Flow | -618.72M |
| Capital Expenditures | -17.30M |
| Free Cash Flow | -636.03M |
| FCF Per Share | -$3.56 |
Full Cash Flow StatementMargins
Gross margin is 77.25%, with operating and profit margins of -205.25% and -252.01%.
| Gross Margin | 77.25% |
| Operating Margin | -205.25% |
| Pretax Margin | -251.01% |
| Profit Margin | -252.01% |
| EBITDA Margin | -202.67% |
| EBIT Margin | -205.25% |
| FCF Margin | -179.73% |
Dividends & Yields
Insmed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.14% |
| Shareholder Yield | -13.14% |
| Earnings Yield | -6.60% |
| FCF Yield | -4.86% |
Dividend DetailsAnalyst Forecast
The average price target for Insmed is $84.29, which is 15.23% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $84.29 |
| Price Target Difference | 15.23% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (5Y) | 48.69% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on March 3, 2011. It was a reverse split with a ratio of 0.1:1.
| Last Split Date | Mar 3, 2011 |
| Split Type | Reverse |
| Split Ratio | 0.1:1 |
Scores
Insmed has an Altman Z-Score of -0.45 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.45 |
| Piotroski F-Score | 3 |